New research shows T-cell receptor sequencing can reveal immune signatures of precancer and cancer in Lynch syndrome carriers, aiding early detection.
Eduardo Vilar-Sanchez, MD, PhD
Advertisement
Eduardo Vilar-Sanchez, MD, PhD, is a Professor (Term Tenure), Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX.
Articles by Eduardo Vilar-Sanchez, MD, PhD
Blood-based T‑cell receptor sequencing reveals immune “fingerprints” in Lynch syndrome, helping track precancers early and paving the way for new cancer surveillance biomarkers.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Accelerated Approval to RP1 Plus Nivolumab in Advanced Melanoma
2
FDA Clears Bria-PROS+ Immunotherapy Trial in Prostate Cancer
3
BRCA1/BRCA2 Test Results Show Widely Varying Breast, Ovarian Cancer Risk
4
Advanced Renal Cell Carcinoma: Interpreting Emerging Evidence for Belzutifan-Based Therapies
5